[Are there any advantages of a fixed combination in the treatment of asthma with respect to safety and tolerability?].
Virchow
C
C
Institut Klinik und Poliklinik für Innere Medizin, Abt. für Pneumologie, Universität Rostock. j.c.virchow@med.uni-rostock.de
D000280:Administration, Inhalation; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000009:adverse effects; D000318:Adrenergic beta-Agonists / Q000008:administration & dosage / Q000009:adverse effects; D000420:Albuterol / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001249:Asthma / Q000188:drug therapy* / Q000401:mortality; D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000009:adverse effects*; D003692:Delayed-Action Preparations; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004338:Drug Combinations; D004347:Drug Interactions; D004983:Ethanolamines / Q000008:administration & dosage / Q000009:adverse effects; D005541:Forced Expiratory Volume / Q000187:drug effects; D000068759:Formoterol Fumarate; D006801:Humans; D007545:Isoproterenol / Q000008:administration & dosage / Q000009:adverse effects; D010349:Patient Compliance; D016032:Randomized Controlled Trials as Topic; D012306:Risk; D000068299:Salmeterol Xinafoate; D015996:Survival Rate; D013618:Tachyphylaxis
D000305:Adrenal Cortex Hormones; D000318:Adrenergic beta-Agonists; D018927:Anti-Asthmatic Agents; D001993:Bronchodilator Agents; D003692:Delayed-Action Preparations; D004338:Drug Combinations; D004983:Ethanolamines; D000068299:Salmeterol Xinafoate; D007545:Isoproterenol; D000420:Albuterol; D000068759:Formoterol Fumarate